Ameritas Investment Partners’s Charles River Laboratories CRL Stock Holding History

Ameritas Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$948K	Sell	4,178 -41	-1%	-$7.3K	0.03%	654
2026 Q1	$728K	Hold	4,219	–	–	0.02%	716
2025 Q4	$842K	Sell	4,219 -350	-8%	-$63.5K	0.03%	672
2025 Q3	$715K	Sell	4,569 -370	-7%	-$58.8K	0.02%	707
2025 Q2	$749K	Sell	4,939 -61	-1%	-$8.13K	0.02%	703
2025 Q1	$753K	Hold	5,000	–	–	0.03%	693
2024 Q4	$923K	Sell	5,000 -45	-0.9%	-$8.67K	0.03%	641
2024 Q3	$994K	Hold	5,045	–	–	0.03%	640
2024 Q2	$1.04M	Hold	5,045	–	–	0.04%	602
2024 Q1	$1.37M	Hold	5,045	–	–	0.05%	506
2023 Q4	$1.19M	Sell	5,045 -74	-1%	-$14.6K	0.04%	548
2023 Q3	$1M	Hold	5,119	–	–	0.04%	565
2023 Q2	$1.08M	Hold	5,119	–	–	0.04%	563
2023 Q1	$1.03M	Hold	5,119	–	–	0.04%	569
2022 Q4	$1.14M	Buy	5,119 +1,725	+51%	+$377K	0.05%	528
2022 Q3	$667K	Hold	3,394	–	–	0.03%	666
2022 Q2	$725K	Hold	3,394	–	–	0.03%	649
2022 Q1	$963K	Sell	3,394 -56	-2%	-$17.3K	0.03%	635
2021 Q4	$1.3M	Sell	3,450 -9	-0.3%	-$3.5K	0.04%	525
2021 Q3	$1.43M	Hold	3,459	–	–	0.05%	442
2021 Q2	$1.28M	Sell	3,459 -15,370	-82%	-$5.13M	0.05%	511
2021 Q1	$5.25M	Sell	18,829 -94	-0.5%	-$26.1K	0.2%	72
2020 Q4	$4.73M	Sell	18,923 -316	-2%	-$75.3K	0.22%	69
2020 Q3	$4.36M	Sell	19,239 -2,177	-10%	-$452K	0.2%	77
2020 Q2	$3.73M	Buy	21,416 +521	+2%	+$83.2K	0.18%	85
2020 Q1	$2.64M	Hold	20,895	–	–	0.15%	113
2019 Q4	$3.19M	Sell	20,895 -2,600	-11%	-$360K	0.14%	124
2019 Q3	$3.11M	Sell	23,495 -425	-2%	-$57K	0.14%	128
2019 Q2	$3.39M	Buy	23,920 +105	+0.4%	+$14.2K	0.15%	108
2019 Q1	$3.46M	Hold	23,815	–	–	0.16%	102
2018 Q4	$2.69M	Hold	23,815	–	–	0.15%	130
2018 Q3	$3.2M	Buy	23,815 +3,500	+17%	+$432K	0.15%	133
2018 Q2	$2.28M	Hold	20,315	–	–	0.11%	195
2018 Q1	$2.17M	Sell	20,315 -1,941	-9%	-$209K	0.1%	223
2017 Q4	$2.44M	Hold	22,256	–	–	0.11%	203
2017 Q3	$2.42M	Buy	22,256 +8,000	+56%	+$822K	0.11%	191
2017 Q2	$1.44M	Buy	14,256 +291	+2%	+$26.8K	0.07%	363
2017 Q1	$1.26M	Sell	13,965 -430	-3%	-$36.5K	0.06%	413
2016 Q4	$1.1M	Hold	14,395	–	–	0.06%	465
2016 Q3	$1.2M	Buy	14,395 +6,935	+93%	+$581K	0.07%	395
2016 Q2	$615K	Buy	7,460 +346	+5%	+$28.5K	0.04%	507
2016 Q1	$540K	Hold	7,114	–	–	0.04%	531
2015 Q4	$572K	Hold	7,114	–	–	0.04%	480
2015 Q3	$452K	Hold	7,114	–	–	0.03%	583
2015 Q2	$500K	Hold	7,114	–	–	0.03%	593
2015 Q1	$564K	Buy	7,114 +206	+3%	+$15.2K	0.04%	547
2014 Q4	$440K	Hold	6,908	–	–	0.03%	646
2014 Q3	$413K	Sell	6,908 -365	-5%	-$20.9K	0.03%	654
2014 Q2	$389K	Hold	7,273	–	–	0.03%	715
2014 Q1	$439K	Sell	7,273 -307	-4%	-$17.9K	0.03%	624
2013 Q4	$402K	Sell	7,580 -196	-3%	-$9.84K	0.03%	676
2013 Q3	$360K	Buy	+7,776	New	+$357K	0.03%	662

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Ameritas Investment Partners's CRL Position: Q2 2026 in Review

Ameritas Investment Partners reduced its Charles River Laboratories (CRL) stake by 0.97% in Q2 2026, selling an estimated $7.3K and leaving 4,178 shares worth $948K. The position accounts for 0.03% of the portfolio, ranked #654.

Ameritas Investment Partners first reported a position in CRL in Q3 2013 and has held it in 52 quarters since. The position peaked at $5.25M in Q1 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Ameritas Investment Partners held 4,178 shares of Charles River Laboratories worth $948K as of Q2 2026.
Ameritas Investment Partners sold 41 Charles River Laboratories shares in Q2 2026, an estimated $7.3K.
Charles River Laboratories made up 0.03% of Ameritas Investment Partners's portfolio in Q2 2026, its #654 holding.
Ameritas Investment Partners first reported a position in Charles River Laboratories in Q3 2013 and has held it in 52 quarters since.
Ameritas Investment Partners's Charles River Laboratories position peaked at $5.25M in Q1 2021.
565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.